Company: CYTK
Filing Date: 2025-05-16
Form Type: 8-K
Source: 0000950170-25-072965
Chunk: 0

Company: CYTOKINETICS INC
Filing Date: 2025-05-16
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

The following is a brief description of each matter voted upon at the Company’s Annual Meeting of Stockholders held on May 14, 2025 (the “ Annual Meeting”), as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. Of the 119,187,691 shares of the Company’s common stock entitled to vote at the Annual Meeting, 110,486,204 shares of common stock, or 92.69% of the total eligible votes to be cast, were represented at the Annual Meeting in person or by proxy, constituting a quorum. A more complete description of each matter is set forth in the Company’s definitive proxy statement for the Annual Meeting, which was filed with the Securities and Exchange Commission on April 10, 2025.

Proposal 1: Election of Three Class III Directors

The stockholders elected John T. Henderson, B. Lynne Parshall, and Muna Bhanji as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified or their earlier resignation or removal. The voting for each director was as follows:

  Name                   For                      Withheld                      Broker                   
                                                                                                         
                                                                                Non-Vote                 
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────
  John T. Henderson               86,834,097                    14,784,943                    8,867,164  
  B. Lynne Parshall               98,261,990                     3,357,050                    8,867,164  
  Muna Bhanji                     89,316,977                    12,302,063                    8,867,164  

Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under Amended and Restated 2004 Equity Incentive Plan by 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors.

The stockholders approved the amendment and restatement of the Amended and Restated 2004 Equity